1IJ Stock Chart & Stats
€7.50
-€0.30(-4.00%)
At close: 4:00 PM EDT
€7.50
-€0.30(-4.00%)
Day’s Range― - ―
52-Week Range€5.05 - €15.00
Previous CloseN/A
Volume350.00
Average Volume (3M)183.00
Market Cap
€53.89M
Enterprise Value-€12.49M
Total Cash (Recent Filing)€118.19M
Total Debt (Recent Filing)€12.85M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Nov 11, 2026EPS Estimate
-1.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.45
Shares Outstanding9,361,490
10 Day Avg. Volume397
30 Day Avg. Volume183
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.28Price Target Upside197.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-5.64
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Prula-cel Efficacy And SafetyThe observed renal responses, remission and steroid reduction suggest meaningful biological activity in a high-need autoimmune setting. The favorable safety profile and FDA alignment support outpatient use and a path toward pivotal testing, creating a potentially scalable, one-time therapy opportunity.
Broad Clinical PipelineProgress across prula-cel, ADI-212 and planned in vivo CAR-T programs gives Adicet multiple shots on goal rather than dependence on one indication. IND clearance and scheduled enrollment create a staged clinical data path that can validate the platform and broaden applications over time.
Low Financial LeverageVery low leverage limits mandatory debt-service pressure and preserves greater flexibility than a heavily indebted biotechnology business. This balance-sheet characteristic can help Adicet direct available resources toward clinical development and withstand operating volatility without significant creditor constraints.
Bears Say
No Commercial Revenue And Persistent LossesThe absence of meaningful product revenue means Adicet has not yet demonstrated a commercial earnings engine and remains dependent on clinical progress for future value creation. Recurring losses also indicate that current operations cannot self-fund development or establish durable operating leverage.
High Cash Burn And Funding DependenceSustained negative operating and free cash flow makes continued access to financing important for maintaining clinical programs. External funding dependence can constrain strategic flexibility and may require additional capital before pivotal development or commercialization, increasing execution and financing pressure.
Shrinking Equity Base And Value ErosionThe substantial decline in equity reflects the cumulative impact of losses and cash consumption despite modest debt. A shrinking capital base reduces financial resilience and signals that shareholder resources are being eroded while the company continues investing in uncommercialized therapies.
Adicet Bio News
1IJ FAQ
What was Adicet Bio’s price range in the past 12 months?
Adicet Bio lowest stock price was €5.05 and its highest was €15.00 in the past 12 months.
What is Adicet Bio’s market cap?
Adicet Bio’s market cap is €53.89M.
When is Adicet Bio’s upcoming earnings report date?
Adicet Bio’s upcoming earnings report date is Nov 11, 2026 which is in 34 days.
How were Adicet Bio’s earnings last quarter?
Adicet Bio released its earnings results on Aug 05, 2026. The company reported -€1.771 earnings per share for the quarter, missing the consensus estimate of -€1.505 by -€0.265.
Is Adicet Bio overvalued?
According to Wall Street analysts Adicet Bio’s price is currently Undervalued.
Does Adicet Bio pay dividends?
Adicet Bio does not currently pay dividends.
What is Adicet Bio’s EPS estimate?
Adicet Bio’s EPS estimate is -1.4.
How many shares outstanding does Adicet Bio have?
Adicet Bio has 9,361,490 shares outstanding.
What happened to Adicet Bio’s price movement after its last earnings report?
Adicet Bio reported an EPS of -€1.771 in its last earnings report, missing expectations of -€1.505. Following the earnings report the stock price went down -21.212%.
Which hedge fund is a major shareholder of Adicet Bio?
Currently, no hedge funds are holding shares in DE:1IJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adicet Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€22.28 (197.10% Upside)
€22.28 (197.10% Upside)
Blogger Sentiment
Bullish
DE:1IJ Sentiment 100%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-60.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Adicet Bio
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
1IJ Stock 12 Month Forecast
Average Price Target
€22.28
▲(197.10% Upside)